Anti-inflammatory effects of salmeterol/fluticasone propionate (SFC) by smoking status in COPD Source: Eur Respir J 2005; 26: Suppl. 49, 204s Year: 2005
Multiple synergistic effects of fluticasone propionate and salmeterol on T-cell activation in bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 250s Year: 2004
Combination therapy with salmeterol and fluticasone propionate (SFC) is more effective than salmeterol (SAL) alone in reducing exacerbations of COPD Source: Eur Respir J 2005; 26: Suppl. 49, 292s Year: 2005
The effect of salmeterol/fluticasone propionate (SFC) on bronchial mucosal neutrophils and IL-8 gene expression in COPD Source: Eur Respir J 2007; 30: Suppl. 51, 354s Year: 2007
The effects of treatment with fluticasone propionate alone and combination with salmeterol on asthma control and airway inflammation Source: Eur Respir J 2003; 22: Suppl. 45, 287s Year: 2003
Comparison of the anti-inflammatory effects of extra-fine HFA-beclomethasone (BDP) versus fluticasone (FP)-DPI on inflammatory markers in exhaled breath in childhood asthma Source: Annual Congress 2007 - Childhood asthma: treatment and follow-up Year: 2007
Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD Source: Eur Respir J 2003; 22: Suppl. 45, 49s Year: 2003
Effects of salmeterol/fluticasone propionate (SFC) on airway inflammation in COPD: a placebo-controlled study of endobronchial biopsies Source: Eur Respir J 2005; 26: Suppl. 49, 203s Year: 2005
Effect of switching from high dose fluticasone propionate (FP) to FP/salmeterol (FSC) on airway inflammation in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 44s Year: 2004
A comparison of suplatast tosilate, a Th2 cytokine inhibitor, and inhaled fluticasone propionate for airway inflammation in mild asthma Source: Eur Respir J 2002; 20: Suppl. 38, 373s Year: 2002
Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol Source: Eur Respir J 2004; 24: Suppl. 48, 291s Year: 2004
Comparison of budesonide and fluticasone propionate on COPD macrophage phagocytosis and killing of bacteria Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014
The effect of fluticasone vs fluticasone plus salmeterol on allergen-induced bronchial inflammation in asthmatic patients. A long-term RCT Source: Eur Respir J 2004; 24: Suppl. 48, 125s Year: 2004
Stable dosing with salmeterol/fluticasone propionate combination ensures long-term asthma control, including airway hyperresponsiveness Source: Eur Respir J 2005; 26: Suppl. 49, 429s Year: 2005
The effects of fluticasone propionate in asthmatic patients Source: Eur Respir J 2004; 24: Suppl. 48, 125s Year: 2004
Comparison of anti-inflammatory and clinical effects of beclomethasone dipropionate and salmeterol in moderate asthma Source: Eur Respir J 2002; 20: 66-72 Year: 2002
Effects of salmeterol/fluticasone propionate (SFC) on airway inflammation in induced sputum in COPD Source: Annual Congress 2005 - Effects of anti-inflammatory drugs on COPD Year: 2005
Dynamics of lung function in children treated with salmeterol/ fluticasone propionate combination (SFC) Source: Eur Respir J 2003; 22: Suppl. 45, 497s Year: 2003
Superiority of the ‘triple‘ therapy of salmeterol/fluticasone propionate (SFC) and tiotropium (TIO) vs. individual components in COPD Source: Annual Congress 2007 - New drugs for COPD Year: 2007
Anti-inflammatory effects of formoterol and fluticasone propionate in bronchial epithelial cells Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease Year: 2015